Succinyltanshinone IIA Displays Stronger Inhibition than Tanshinone IIA In Breast Cancer Cell by Mitochondria-Dependent Apoptosis

Fengmei Wang,Fuxiang Mao,Shengwen Chen,Caihong Zheng,Lishe Gan,Linwei Zeng,Wei Yu,Changxin Zhou
2020-01-01
Latin american journal of pharmacy
Abstract:A novel compound, succinyltanshinone IIA (STA), modified from the natural product tanshinone IIA (TA), was recently reported to exhibit higher potency than amphotericin B against fungi. However, related cytotoxicity in breast cancer between STA and TA remains unclear. In this study, STA showed stronger inhibitory activity on breast cancer cell growth than TA in both human epidermal growth factor receptor 2 (HER2) and estrogen receptor (ER) positive breast cancer. Similarly, STA and TA displayed higher apoptotic effect in ER positive cells than HER2 positive breast cancer cells by detecting DNA fragmentation level. Furthermore, we determined that STA significantly reduced Bcl-2 protein in HER2 positive cancer cells as compared to TA. In both STA and TA treated ER positive cancer cells, Akt phosphorylation levels were up-regulated. Taken together, STA is a novel potential anticancer compound in vitro, and its higher potency against breast cancer as compared TA may lead to promising bioavailability in clinical studies.
What problem does this paper attempt to address?